ATE391138T1 - Neue komplexe methylierter cyclodextrine - Google Patents

Neue komplexe methylierter cyclodextrine

Info

Publication number
ATE391138T1
ATE391138T1 AT03702684T AT03702684T ATE391138T1 AT E391138 T1 ATE391138 T1 AT E391138T1 AT 03702684 T AT03702684 T AT 03702684T AT 03702684 T AT03702684 T AT 03702684T AT E391138 T1 ATE391138 T1 AT E391138T1
Authority
AT
Austria
Prior art keywords
cyclodextrin
new complexes
methylated cyclodextrins
beta
directed
Prior art date
Application number
AT03702684T
Other languages
English (en)
Inventor
Tomi Jarvinen
Janne Mannila
Pekka Jarho
Original Assignee
Pedipharm Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pedipharm Oy filed Critical Pedipharm Oy
Application granted granted Critical
Publication of ATE391138T1 publication Critical patent/ATE391138T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03702684T 2002-02-20 2003-02-20 Neue komplexe methylierter cyclodextrine ATE391138T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20020333A FI111733B (fi) 2002-02-20 2002-02-20 Uudet metyloidut syklodekstriinikompleksit

Publications (1)

Publication Number Publication Date
ATE391138T1 true ATE391138T1 (de) 2008-04-15

Family

ID=8563271

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03702684T ATE391138T1 (de) 2002-02-20 2003-02-20 Neue komplexe methylierter cyclodextrine

Country Status (10)

Country Link
US (1) US7423026B2 (de)
EP (1) EP1476472B1 (de)
AT (1) ATE391138T1 (de)
AU (1) AU2003205807B2 (de)
CA (1) CA2476833C (de)
DE (1) DE60320088T2 (de)
ES (1) ES2301780T3 (de)
FI (1) FI111733B (de)
NZ (1) NZ535153A (de)
WO (1) WO2003070774A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI113340B (fi) * 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
MX2007015838A (es) * 2005-06-20 2008-02-22 Unimed Pharmaceutical Inc Dronabinol para el tratamiento de migranas.
LT2280687T (lt) 2008-03-26 2019-08-26 Stichting Sanammad Kramtomosios gumos kompozicijos, apimančios kanabinoidus
US8735374B2 (en) * 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
SG190024A1 (en) * 2010-11-25 2013-06-28 Aop Orphan Pharmaceuticals Ag Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin
US9744128B2 (en) 2014-06-05 2017-08-29 Mastix LLC Method for manufacturing medicated chewing gum without cooling
WO2017180953A1 (en) 2016-04-15 2017-10-19 Ronald Silver Cannabis infused sweeteners and elixirs
US20220087972A9 (en) 2016-04-15 2022-03-24 Sre Wellness, Inc. Cannabinoid Compositions
EP3442522A4 (de) 2016-04-15 2020-01-01 SRE Wellness, Inc. Verfahren zur herstellung von hydrophilisiertem cannabisöl unter verwendung von emulgatoren und zugehörige cannabinoidzusammensetzungen
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
CA3036585A1 (en) * 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
US11097206B2 (en) 2016-12-09 2021-08-24 Orochem Technologies Inc. Method for producing purified steviol product using simulated moving bed chromatography
US10058531B1 (en) * 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
US11179340B2 (en) * 2017-12-29 2021-11-23 TGC Network LLC Cannabidiol dosage form
CA3088358A1 (en) * 2018-01-13 2019-07-18 Pure Green Pharmaceuticals, Inc. Transformation of cannabinol and terpene oils into water soluble dry powders for solid form sublingual delivery
US20200016091A1 (en) * 2018-07-16 2020-01-16 Orochem Technologies, Inc. Water-soluble cannabidiol
WO2020028897A1 (en) * 2018-08-03 2020-02-06 Lilu's Garden, Ltd. CONSTRUCT OF β-CYCLODEXTRIN AND CANNABINOID GUEST COMPLEX AND PROCESSES FOR PRODUCING A PASTE COMPRISING THE SAME
CA3122735A1 (en) 2018-12-14 2020-06-18 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
US11660283B2 (en) 2018-12-19 2023-05-30 Joyn Botanicals Ltd. Cannabinoid-containing composition
CN110123876A (zh) * 2019-05-30 2019-08-16 汉义生物科技(北京)有限公司 一种含有非精神活性大麻素的包合物及其制备方法
CN110204426B (zh) * 2019-07-02 2023-05-30 梁志全 一种水溶性cbd的制备方法及水溶性cbd
CN110433133A (zh) * 2019-08-19 2019-11-12 中国人民解放军军事科学院军事医学研究院 治疗创伤后应激障碍的大麻二酚鼻用制剂
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CA3158415A1 (en) * 2019-10-21 2021-04-29 Esolate Ltd Compositions comprising superfine compounds and production thereof
CA3118754A1 (en) 2019-12-16 2021-06-16 Mehmet Nevzat PISAK Cannabinoid compositions with high solubility and bioavailabilty
WO2021144262A1 (de) * 2020-01-13 2021-07-22 Rrw B.V. Wässrige lösung einer lipophilen verbindung
EP3919046A1 (de) 2020-06-02 2021-12-08 Athenion AG Verfahren zur solubilisierung von natürlichen, endogenen und synthetischen cannabinoiden
EP4167979A1 (de) * 2020-06-19 2023-04-26 Cannovex BV Lungenformulierung mit cannabinoiden
AU2021308671A1 (en) * 2020-07-17 2023-03-02 Canna-Chemistries Llc Solid Δ9-tetrahydrocannabinol ( Δ9-THC) compositions
CN114748429A (zh) * 2020-12-29 2022-07-15 汉义生物科技(北京)有限公司 一种水溶性大麻素制剂及其制备方法
EP4611740A1 (de) * 2022-11-02 2025-09-10 Progressive Therapeutics, Inc. Cannabinoidformulierungen und verwendung zur behandlung von emotionalen störungen und sexueller dysfunktion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU194858B (en) * 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5180716A (en) 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
WO2003033025A2 (en) 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
FI113340B (fi) 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit

Also Published As

Publication number Publication date
US20050090468A1 (en) 2005-04-28
WO2003070774A1 (en) 2003-08-28
FI111733B (fi) 2003-09-15
NZ535153A (en) 2006-03-31
AU2003205807A1 (en) 2003-09-09
DE60320088D1 (de) 2008-05-15
AU2003205807B2 (en) 2008-11-20
ES2301780T3 (es) 2008-07-01
FI20020333A0 (fi) 2002-02-20
EP1476472B1 (de) 2008-04-02
US7423026B2 (en) 2008-09-09
DE60320088T2 (de) 2009-06-04
CA2476833A1 (en) 2003-08-28
CA2476833C (en) 2011-02-01
EP1476472A1 (de) 2004-11-17

Similar Documents

Publication Publication Date Title
ATE391138T1 (de) Neue komplexe methylierter cyclodextrine
FI20020334A7 (fi) Luonnon syklodekstriinin uudet kompleksit
BR0109131A (pt) Fator viii modificado
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
WO2002055562A3 (en) Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
DE60139733D1 (de) Verschleißfeste Legierung auf Eisenbasis
NO20031473D0 (no) Prosessering av hydrocarbon gass
ATE396745T1 (de) Complex enthaltend modafinil und cyclodextrin
ATE330017T1 (de) Kallikrein gen
ATE359279T1 (de) Moschus-geruchsstoffe
MXPA03008076A (es) Isoflavonas dimericas.
DE50205211D1 (de) Radial dämpfendes buchsengummilager
ID30526A (id) Prekursor pewangi
ATE483714T1 (de) Podophyllotoxine als antiproliferative mittel
YU3802A (sh) Tableta za sisanje, koja sadrži ambroksol
ATE427970T1 (de) Verbesserte mikrogele und filme
BR0012751A (pt) Benzofuranos serotonérgicos
ATE280169T1 (de) Serotonerge benzothiophene
BR0209737A (pt) Precursores para cetonas e aldeìdos
AU2001285850A1 (en) Novel macrocyclic ketones
ATE318367T1 (de) Gasturbinenstator
DE60133600D1 (de) C7-carbamoyloxysubstituierte taxane als antitumormittel
DE60138853D1 (de) C10-taxanester als antitumormittel
HRP20031068B1 (en) Chloromethylation of thiophene
DE60213827D1 (de) Antikörper gegen Caspase-8, ihre Herstellung und Verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties